Basic approach to inflammatory ulcers

Dermatologic Therapy

Volumn 19, Issue 6, 2006, Pages 365-376

  Panuncialman, Jaymie ^a   Falanga, Vincent ^a,b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Connective tissue diseases; Inflammatory ulcers; Pyoderma gangrenosum; Vasculitis

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DAPSONE; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PREDNISONE; PROSTACYCLIN; RETINOIC ACID; RIBAVIRIN; STANOZOLOL; TACROLIMUS; THALIDOMIDE; UNINDEXED DRUG; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; AVASCULAR NECROSIS; BLOOD EXAMINATION; BLOOD VESSEL FUNCTION; CATARACT; CLINICAL FEATURE; CRYOGLOBULINEMIA; CRYOPRECIPITATE; DEBRIDEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ELECTROLYTE DISTURBANCE; GLUCOSE INTOLERANCE; HISTOLOGY; HUMAN; HYPERTENSION; LABORATORY DIAGNOSIS; LEUKEMIA; LOW DRUG DOSE; MICROTHROMBUS; MICROTHROMBUS ULCER; MYOPATHY; OSTEOPOROSIS; PHYSICAL EXAMINATION; PSYCHOSIS; PYODERMA GANGRENOSUM; RECURRENCE RISK; REVIEW; RHEUMATOID ULCER; SCLERODERMA; SIDE EFFECT; SKIN EXAMINATION; SKIN ULCER; ULCEROGENESIS; VASCULITIS;

HUMANS; INFLAMMATION; MEDICAL HISTORY TAKING; PHYSICAL EXAMINATION; SKIN CARE; SKIN ULCER;

EID: 33845681129     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2006.00097.x     Document Type: Review

References (39)

1. Grey Joseph E, Enoch S, Harding KG. ABC of wound healing: wound assessment. Br Med J 2006: 332: 285-288.
2. Patel G, Grey JE, Harding KG. ABC of wound healing: uncommon causes of ulceration. Br Med J 2006: 332: 594-596.
3. Falanga V. Inflammatory Ulcer. Leg ulcers. In: Morrison M, Moffett C, Franks P, eds. Edinburgh, UK: Elsevier. In press.
4. Falanga V. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen 2000: 5: 347-352.
5. Ehling A, Karrer S, Klebl F, et al. Therapeutic management of pyoderma gangrenosum. Arthritis Rheum 2004: 50: 3076-3082.
6. Falabella A, Falanga V. Uncommon causes of ulcers. Clin Plast Surg 1998: 25: 467-479.
7. Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002: 18: 1412-1418.
8. Powell FC, O'Kane M. Management of pyoderma gangrenosum. Dermatol Clin 2002: 2: 347-345.
9. Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003: 30: 97-107.
10. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996: 34: 395-409.
11. Eichorn PJ. Pyoderma gangrenosum. Dermatol Ther 2001: 14: 102-110.
12. Chow RKP, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996: 34: 1047-1060.
13. Burruss JB, Farmer ER, Callen JP. Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol 1996: 35: 720-724.
14. Altmann J, Mopper C. Pyoderma gangenosum treated with sulfone drugs. Minn Med 1966: 49: 22-26.
15. Hecker MS, Lebwohl MG. Recalcitrant pyoderma gangrenosum treatment with thalidomide. J Am Acad Dermatol 1998: 38: 490-501.
16. Noussari HC, Lynch W, Anhalt GJ, Petri M. The effectiveness of mycophenolate mofetil refractory pyoderma gangrenosum. Arch Dermatol 1998: 134: 1509-1511.
17. Hohenleutner U, Volker DM, Michel S, Landthaler M. Mycophenolate mofetil and cyclosporine for the treatment of recalcitrant pyoderma gangrenosum. Lancet 1997: 350: 1748.
18. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infiximab and adalimumab. Br J Dermatol 2005: 152: 1059-1061.
19. Brooklyn TN, Dunnhill MGS, Shetty A, et al. Infiximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut 2006: 55: 505-509.
20. Fridey JL, Kaplan AA. Indications for therapeutic plasma exchange. UpToDate 11.1 2003 Available from URL: www.uptodate.com.
21. Hagman JH, Carrozo AM, Campione E, Romanelli P, Chimenti S. The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum. J Dermatolog Treat 2001: 12: 19-22.
22. Jolles S, Niclasse S, Benson E. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 1999: 140: 564-565.
23. De Imus G, Golomb C, Wilkel C, et al. Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J Am Acad Dermatol 2001: 44: 61-66.
24. Öien RF, Håkkanson A, Hansen BU. Leg ulcers in patients with rheumatoid arthritis - a prospective study of etiology, wound healing and pain reduction after pinch grafting. Rheumatology 2001: 40: 816-820.
25. Hirche D, Rubbert A, Lunau L, et al. Successful treatment of refractory rheumatoid arthritis-associated leg ulcerations with adalimumab. Br J Dermatol 2005: 152: 1062-1063.
26. Schuppe HC, Richter-Hintz D, Stierle HE, et al. Topical tacrolimus for recalcitrant leg ulcer in rheumatoid arthritis. Rheumatology 2000: 39: 105-106.
27. Kanekura T, Mochitomi Y, Fujimoto S, et al. Granulocyte and monocyte adsorption apheresis for leg ulcers in a patient with rheumatoid arthritis. J Am Acad Dermatol 2005: 52: 1108-1109.
28. Chung L, Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 2006: 5: 125-128.
29. Rademaker M, Cooke E, Almond N, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Reynaud's phenomenon in patients with systemic sclerosis. Br Med J 1989: 298: 561-564.
30. Wigley F, Wise R, Seibold J, et al. Intravenous ilosprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis. Ann Intern Med 1994: 120: 199-206.
31. Korn J, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004: 50: 3985-3993.
32. Paquette D, Badiavas E, Falanga V. Short-contact topical tretinoin therapy to stimulate granulation tissue in chronic wounds. J Am Acad Dermatol 2001: 45: 382-386.
33. Sais G, Vidaller A, Jucgia A, et al. Prognostic factors in leukocytoclastic vasculitis. Arch Dermatol 1998: 134: 309-315.
34. Braverman IM. The role of blood vessels and lymphatics in cutaneous inflammatory processes: an overview. Br J Dermatol 1983: 109 (Suppl. 25): 89-98.
35. Gibson LE. Cutaneous vasculitis update. Dermatologic Clinics 2001: 19: 603-615.
36. Amdo T, Welker J. An approach to the diagnosis and treatment of cryofibrinogenemia. Am J Med 2004: 116: 332-337.
37. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol 2002: 55: 4-13.
38. Paquette D, Falanga V. Leg ulcers. Clin Geriatr Med: 18: 77-88, vi.
39. Donohue KG, Saap L, Falanga V. Cholesterol crystal embolization: an atherosclerotic disease with frequent and varied cutaneous manifestations. J Eur Acad Dermatol Venereol 2003: 17: 504-511.